Table 4.
Year of surrogate endpoints of four groups stratified by TNM staging
| Total patients | Year of surrogate endpoints | |||
|---|---|---|---|---|
| 8th staging | OS | PFS | LRFS | DMFS |
| I | 1 | 1 | 1 | 1 |
| II | 3 | 3 | 3 | 4 |
| III | 5 | 5 | 4 | 4 |
| IVA | 5 | 5 | 3 | 3 |
| EBV<103 | ||||
| I | 1 | 1 | 1 | 1 |
| II | 3 | 3 | 3 | 4 |
| III | 5 | 4 | 3 | 3 |
| IVA | 5 | 4 | 3 | 3 |
| 103≤EBV<105 | ||||
| I | 1 | 1 | 1 | 1 |
| II | 3 | 2 | 2 | 1 |
| III | 4 | 4 | 4 | 4 |
| IVA | 4 | 3 | 3 | 2 |
| EBV≥105 | ||||
| I | ||||
| II | 1 | 4 | 4 | 1 |
| III | 3 | 3 | 2 | 4 |
| IVA | 4 | 4 | 3 | 3 |
EBV, plasma Epstein-Barr viral; OS, overall survival; PFS, progression-free survival; LRFS, loco-regional recurrence-free survival; DMFS, distant metastasis-free survival